Race Oncology Ltd has released a press release.
Race appoints leading haematologist to support Bisantrene
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Race signs agreement for Bisantrene NPP in Israel
- Race appoints Biosynergy to pursue Bisantrene licensing
- September 2018 Quarterly Report
- Appendix 4E & Financial Statements
- June 2018 Quarterly Report
Later from Racura Oncology
- Race Receives $228k R&D Tax Incentive Refund
- Principal Investigator appointed for Bisantrene
- Race files Bisantrene IND with FDA
- Bisantrene IND Update
- Bisantrene AML trial to start in Israel
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology